{"filings":[{"id":68206,"accession_number":"0001193125-26-221624","cik":1369290,"company_name":"MYOMO, INC.","ticker":"MYO","form_type":"8-K","filed_at":"2026-05-13T20:10:16+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Myomo appoints Joseph Manko Jr., founder of Horton Capital, as director","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Joseph M. Manko Jr. appointed as Class I director effective May 9, 2026, through 2027 annual meeting.","Manko is Senior Principal of Horton Capital Management, a significant Myomo shareholder.","Over 25 years in investment banking, private equity, and corporate strategy.","Also serves on boards of Safeguard Scientifics and KORU Medical Systems.","Will receive standard non-employee director compensation ($60k cash + $85k RSUs)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":40570585.65,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92453,"accession_number":"0001193125-26-211928","cik":1369290,"company_name":"MYOMO, INC.","ticker":"MYO","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Myomo Q1 revenue $10.1M (+3% YoY); net loss narrows to $3.0M; guides Q2 $10.3M-$10.8M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $10.1M (+3% YoY), net loss $3.0M ($0.07/sh) vs $3.5M loss ($0.08/sh) in Q1 2025.","Gross margin expanded to 68.2% (up 100 bps); operating expenses down 1% YoY to $10.1M.","Orders received 239 (+12% YoY); backlog 226 (+14% vs Dec 2025); pipeline adds up 7% sequentially.","Recurring patient source revenue reached 49% of total, up from 25% a year ago.","Q2 2026 revenue guidance $10.3M-$10.8M; FY 2026 revenue reiterated at $43M-$46M."],"consensus_eps_estimate":-0.1151,"consensus_eps_actual":-0.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":10113288.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":40570585.65,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":92452,"accession_number":"0001193125-26-159060","cik":1369290,"company_name":"MYOMO, INC.","ticker":"MYO","form_type":"8-K","filed_at":"2026-04-16T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Myomo appoints William J. Febbo to Board, effective April 14, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Febbo, 57, is CEO of Performance Health Systems and former CEO of OptimizeRx (OPRX), where he grew revenue from $5M to $92M.","He received 45,000 RSUs vesting on first anniversary, plus $60K annual cash retainer and $85K annual RSU retainer.","Appointment expands Board to six directors; Febbo serves as Class II director until 2028 annual meeting.","Chairman Paul Gudonis cited Febbo's expertise in scaling direct-to-patient healthcare and capital markets credibility.","Febbo co-founded Merriman Holdings and Digital Capital Network; also MIT linQ faculty and Harvard Business School mentor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":40570585.65,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":103301,"accession_number":"0001193125-26-098504","cik":1369290,"company_name":"MYOMO, INC.","ticker":"MYO","form_type":"8-K","filed_at":"2026-03-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Myomo Q4 revenue falls 6% to $11.4M; net loss widens to $3.8M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $11.4M (-6% YoY); full year $40.9M (+26% YoY).","Q4 net loss $3.8M ($0.09/sh) vs loss $0.3M in Q4 2024; full year loss $15.6M.","Record 241 authorizations/orders in Q4; 42% of revenue from recurring sources (vs 26% a year ago).","Introduces 2026 revenue guidance $43M-$46M; Q1 2026 guidance $9.0M-$9.5M.","Cash $18.4M at Dec 31, 2025; gross margin 68.6% in Q4 vs 71.4% prior year."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":40570585.65,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119553,"accession_number":"0001193125-25-320896","cik":1369290,"company_name":"MYOMO, INC.","ticker":"MYO","form_type":"8-K","filed_at":"2025-12-16T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Myomo CEO & CFO take 10% salary cut in 2026, receiving RSUs at 115% of foregone amount","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Paul Gudonis voluntarily reduces 2026 base salary 10% ($40,000) for RSUs worth $46,000 (115% of foregone).","CFO David Henry voluntarily reduces 2026 base salary 10% ($30,000) for RSUs worth $34,500 (115% of foregone).","RSUs granted quarterly from Jan 12, 2026, vesting after three months; company may cancel program before Jan 12."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":40570585.65,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":119552,"accession_number":"0001193125-25-274238","cik":1369290,"company_name":"MYOMO, INC.","ticker":"MYO","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["1.01","2.02","2.03","3.02","9.01"],"status":"ready","headline":"Myomo Q3 revenue $10.1M (+10% YoY); net loss $0.09/shr; FY guidance $40-42M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $10.1M, up 10% YoY; 186 units sold (+16%), ASP ~$54,200 (-5%).","Gross margin 63.8% vs 75.4% YoY due to higher costs, lower ASP, and unfavorable overhead absorption.","Net loss $3.7M ($0.09/shr) vs $1.0M loss ($0.03/shr) a year ago; operating loss $3.5M.","New $17.5M Avenue Capital loan; $12.5M funded, pro forma cash $20.1M after debt repayment and fees.","Reiterated FY2025 revenue guidance $40-42M; Q3 authorizations/orders 229 (best quarter of year)."],"consensus_eps_estimate":-0.1091,"consensus_eps_actual":-0.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":29574746.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":40570585.65,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":136120,"accession_number":"0000950170-25-106562","cik":1369290,"company_name":"MYOMO, INC.","ticker":"MYO","form_type":"8-K","filed_at":"2025-08-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Myomo Q2 revenue $9.7M (+28%) but operating loss widens; cuts FY2025 guidance to $40-42M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $9.7M (+28% YoY), revenue units 178 (+13%), ASP ~$54,200 (+14%).","Orders/authorizations 207 (-3%), backlog 230 units (-18%), pipeline adds 816 (+49%).","Operating loss $4.6M vs $1.1M; net loss $0.11/share vs $0.03; gross margin 62.7% vs 70.8%.","Cash $15.5M after $4M borrowings; ops used $8.9M cash; workforce cut ~8%, aiming to save $2M annually.","FY2025 revenue guidance cut to $40-42M from $50-53M (23-29% YoY growth); Q3 guided $9.5-10.0M."],"consensus_eps_estimate":-0.1071,"consensus_eps_actual":-0.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":19484048.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":40570585.65,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153175,"accession_number":"0000950170-25-087709","cik":1369290,"company_name":"MYOMO, INC.","ticker":"MYO","form_type":"8-K","filed_at":"2025-06-18T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Myomo sets 2028 revenue target of $100M, gross margin 70-72% at Investor Day","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Aspirational goal of $100M annual revenue by 2028, including $15M international and $20M O&P channel revenue.","Manufacturing capacity to reach 250 MyoPros/month with existing plus new space available in July 2025.","Cost-reduction projects targeting ~200 bps gross margin improvement quarterly by end of 2026.","Targets: gross margin 70-72%, EBITDA margin 15-20%, cash flow breakeven at $17-18M quarterly revenue.","Private payer contracts cover 27M+ lives; lead generation recovered from early Q1 2025 challenges."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":40570585.65,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153174,"accession_number":"0000950170-25-086306","cik":1369290,"company_name":"MYOMO, INC.","ticker":"MYO","form_type":"8-K","filed_at":"2025-06-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Myomo stockholders elect Heather Getz as Class II director, ratify CBIZ as auditor for FY2025","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Heather Getz elected as Class II director for three-year term expiring at 2028 annual meeting; 10,294,384 for, 1,888,001 withheld, 12,131,966 broker non-votes.","Ratification of CBIZ CPAs P.C. as independent auditor for fiscal year ending Dec 31, 2025 passed: 23,797,191 for, 392,407 against, 124,753 abstain, no broker non-votes.","Annual Meeting held June 11, 2025; record date Apr 14, 2025 with 35,978,651 shares outstanding (including unvoted broker shares).","No other matters were submitted or voted on at the Annual Meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":40570585.65,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153173,"accession_number":"0000950170-25-065657","cik":1369290,"company_name":"MYOMO, INC.","ticker":"MYO","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Myomo Q1 revenue $9.8M (+162%); record 700 pipeline adds; guides Q2 $9.0-9.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $9.8M (+162% YoY) on 182 units (+100%); gross margin 67.2% (up 600 bps).","Net loss $3.5M ($0.08/share) vs $3.8M loss last year; adj. EBITDA $(2.8)M.","Record 700 patients added to pipeline (+42% YoY); backlog 249 units (-9%).","Q2 2025 revenue guidance $9.0-9.5M; FY2025 reaffirmed at $50-53M.","Medicare Part B patients 59% of Q1 revenue; 45% of revenue from in-quarter authorizations."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":9831814.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":40570585.65,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":153172,"accession_number":"0000950170-25-052686","cik":1369290,"company_name":"MYOMO, INC.","ticker":"MYO","form_type":"8-K","filed_at":"2025-04-10T23:59:59+00:00","items":["4.01","5.02","7.01","9.01"],"status":"ready","headline":"Myomo names CBIZ as new auditor; two directors exit board","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Marcum LLP resigned as auditor April 8; CBIZ CPAs engaged after acquiring Marcum's attest business.","No disagreements with Marcum; but a material weakness in IT general controls was reported in the 2024 10-K.","Director Amy Knapp (served since 2016) not standing for reelection at June 2025 annual meeting; no disagreement.","Director Yitzchak Jacobovitz (since 2023) not standing for reelection; will transition to board observer role."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":40570585.65,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171950,"accession_number":"0000950170-25-036280","cik":1369290,"company_name":"MYOMO, INC.","ticker":"MYO","form_type":"8-K","filed_at":"2025-03-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Myomo Q4 revenue $12.1M record, first positive op. cash flow; guides FY2025 $50-53M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $12.1M (+154% YoY); 220 units shipped (+106%); ASP ~$54,900 (+23%).","First positive quarterly cash flow from operations at $3.4M; free cash flow $2.5M.","Record 233 MyoPro authorizations/orders (+27%); backlog 272 units (+18%).","Net loss narrowed to $0.3M ($0.01/sh) from $2.5M ($0.07/sh); Adjusted EBITDA $0.2M (first positive).","FY2025 revenue guidance $50-53M (+54-63% YoY); Q1 expected $9.0-9.5M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":40570585.65,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171949,"accession_number":"0000950170-25-023403","cik":1369290,"company_name":"MYOMO, INC.","ticker":"MYO","form_type":"8-K","filed_at":"2025-02-20T23:59:59+00:00","items":["1.01","2.04","2.03","9.01"],"status":"ready","headline":"Myomo enters $3M term loan with SVB; revises revolver Medicare concentration limit","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["New $3M term loan available until Feb 28, 2026; repayable in 36 monthly installments from Mar 1, 2026, maturing Feb 1, 2029.","Interest on term loan at greater of 5.0% or prime minus 1.0%; prepayment fee 1%-3% based on prepayment year.","Revolving line Medicare receivables concentration limit raised to 50% (from prior); German subsidiary deposit limit increased to $1.5M.","Existing $4M revolver (expandable to $5.5M) retains July 11, 2026 maturity; 8.5% floor or prime+0.5% interest."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":40570585.65,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188951,"accession_number":"0001193125-24-271571","cik":1369290,"company_name":"MYOMO, INC.","ticker":"MYO","form_type":"8-K","filed_at":"2024-12-05T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Myomo prices $15M public offering of 3M shares at $5.00; underwriter option exercised in full","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["3,000,000 shares priced at $5.00 each; gross proceeds of $15.0M expected before expenses.","Net proceeds estimated at ~$15.8M after underwriting discounts and offering expenses.","Underwriter's 30-day option for 450,000 additional shares exercised in full.","Proceeds to fund advertising, headcount, O&P channel, product development, working capital.","Offering expected to close December 6, 2024; Craig-Hallum sole managing underwriter."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":40570585.65,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":188950,"accession_number":"0000950170-24-122298","cik":1369290,"company_name":"MYOMO, INC.","ticker":"MYO","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Myomo Q3 revenue record $9.2M (+81% YoY); FY guidance raised to $30-31M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record Q3 product revenue $9.2M, +83% YoY; net loss $1.0M ($0.03/sh) vs $2.0M loss year ago.","Gross margin 75.4%, +670 bps; backlog record 316 units (+71%); 225 MyoPro orders (+44%).","Raised FY2024 revenue guidance to $30-31M from prior $28-30M; expects Q4 rev $9.5-10.5M.","Cash $7.0M; expects approaching operating cash flow breakeven in Q4.","Cost per pipeline add $1,618, down 25%; 1,263 patients in pipeline (+21%)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":20482742.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":40570585.65,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205423,"accession_number":"0000950170-24-096326","cik":1369290,"company_name":"MYOMO, INC.","ticker":"MYO","form_type":"8-K","filed_at":"2024-08-13T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Myomo signs 88-month lease for 36,208 sq ft in Burlington, MA for HQ and manufacturing","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Lease for approx. 36,208 rentable sq ft at 45 Blue Sky Drive; monthly rent starts at $96,250 and escalates over 8-year term.","Phase 1 occupancy of 28,708 sq ft expected by Nov 15, 2024; Phase 2 (7,500 sq ft) by June 1, 2025.","Tenant improvement allowance of $700,000; $375,000 letter of credit cash-collateralized.","Fixed monthly rent ranges from $96,250 (first year) to $147,849 (year 8); term approx. 88 months.","One five-year extension option subject to net income and continuous occupancy conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":40570585.65,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205422,"accession_number":"0000950170-24-091801","cik":1369290,"company_name":"MYOMO, INC.","ticker":"MYO","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Myomo Q2 2024 revenue $7.5M (+77% product revenue); record 213 MyoPro orders","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Product revenue $7.5M (+77% YoY); total revenue $7.5M (+26% YoY) reflecting prior-year license fee.","Record 213 MyoPro authorizations/orders (+70% YoY); backlog 282 units (+58% YoY).","1,179 patients in pipeline (+22% YoY); 550 new candidates added in Q2 (+35% YoY).","Gross margin 70.8% (product GM up 1,030 bps to 70.8%); net loss $1.1M ($0.03 EPS).","Q3 revenue guidance $8.0-8.5M; FY2024 revenue target $28-30M; targeting Q4 operating cash flow breakeven."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.13,"consensus_revenue_estimate":null,"consensus_revenue_actual":11275156.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":40570585.65,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205421,"accession_number":"0001193125-24-179060","cik":1369290,"company_name":"MYOMO, INC.","ticker":"MYO","form_type":"8-K","filed_at":"2024-07-15T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Myomo enters $4M revolving credit facility with Silicon Valley Bank","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Revolver up to $4M (expandable to $5.5M); interest rate greater of 8.50% or prime + 0.50%.","Facility secured by all assets except intellectual property; matures July 2026.","Fees include $20K commitment fee, 0.50% anniversary fee, 0.50% unused line fee, and 1% termination fee.","Proceeds for working capital and general business purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":40570585.65,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":205420,"accession_number":"0000950170-24-081953","cik":1369290,"company_name":"MYOMO, INC.","ticker":"MYO","form_type":"8-K","filed_at":"2024-07-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Myomo expects record Q2 revenue $7.2M-$7.4M, up 92-97% sequentially","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q2 revenue $7.2M-$7.4M, 92-97% sequential increase, highest ever.","Revenue units 155-160, up 70-76% vs Q1's 91 units.","Record pipeline additions ~550, record authorizations/orders ~210.","CMS payments faster than anticipated; now booking Medicare Part B revenue on delivery from July 1.","Exited Q2 with nearly 150 employees; hiring on track."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.13,"consensus_revenue_estimate":null,"consensus_revenue_actual":11275156.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":40570585.65,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222333,"accession_number":"0001193125-24-157320","cik":1369290,"company_name":"MYOMO, INC.","ticker":"MYO","form_type":"8-K","filed_at":"2024-06-07T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Myomo shareholders elect Crowley and Morris as Class I directors, ratify Marcum as auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Thomas A. Crowley received 9,246,482 votes for, 1,049,041 withheld, and 11,747,021 broker non-votes.","Milton M. Morris received 10,225,559 votes for, 71,194 withheld, and 11,745,791 broker non-votes.","Ratification of Marcum LLP as independent auditor: 21,615,373 for, 425,595 against, 1,576 abstain.","No other matters were voted on at the annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.0,"calibrated_materiality_score":0.0,"market_cap_usd":40570585.65,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222332,"accession_number":"0000950170-24-055687","cik":1369290,"company_name":"MYOMO, INC.","ticker":"MYO","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Myomo Q1 revenue $3.8M (+9% YoY); backlog record 275 units; net loss $3.8M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $3.8M (+9% YoY); product revenue $3.75M; revenue units 91 (+14%).","Net loss $3.8M ($0.10/share) vs $2.6M loss a year ago; operating loss $3.9M.","Gross margin 61.2% (down 580bps) on lower ASP, higher warranty reserve and material costs.","Record backlog 275 units (+56%), includes 83 Medicare Part B; orders/authorizations 180 (+48%).","Q2 revenue guidance >$5M; FY2024 guidance $28M-$30M; expects operating cash flow breakeven by Q4 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.1,"consensus_revenue_estimate":null,"consensus_revenue_actual":3754389.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":40570585.65,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":222331,"accession_number":"0000950170-24-053228","cik":1369290,"company_name":"MYOMO, INC.","ticker":"MYO","form_type":"8-K","filed_at":"2024-05-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Myomo receives first lump sum Medicare reimbursements for MyoPro under new CMS fees","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["CMS through DME MACs remitted lump sum reimbursements for MyoPros to Medicare Part B beneficiaries.","Payments based on published fees for HCPCS codes L8701 and L8702 effective April 1, 2024.","All four regional DME MACs have remitted payments; first claim paid for a MyoPro Center of Excellence provider.","CEO states greater clarity of reimbursement for channel partners and health professionals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":40570585.65,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}